ConductScience.org, home

Library / Trial comparisons

Intensive vs Standard: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.02020.005560.0707wilsonClinicalTrials.gov
Risk in group 20.040.01570.0984wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.0198-0.080.0362newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.5050.09462.69logClinicalTrials.gov
Odds ratio, group 1 over group 20.4950.08862.77logClinicalTrials.gov
Number needed to treat, for one fewer death from any cause on Intensive than on Standard50.5from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Intensive
Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg~Anti-hypertensive therapy to SBP 130 mm Hg: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
299EG000ClinicalTrials.gov
Group 2Standard
Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg~Anti-hypertensive therapy to SBP 145 mm Hg: Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
4100EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, all-cause mortalityClinicalTrials.gov
Time frameAdverse event data were collected throughout a participant's study completion, an average of 36 monthsClinicalTrials.gov

Trial 8

FieldValueSource
TitleIntensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older PeopleClinicalTrials.gov
NCT numberNCT01650402ClinicalTrials.gov
PhasesNAClinicalTrials.gov
ConditionsHypertension, Systolic, Cerebrovascular DiseaseClinicalTrials.gov
InterventionsAnti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm HgClinicalTrials.gov
Lead sponsorUConn HealthClinicalTrials.gov
Results first posted2020-10-30ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01650402?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.